Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment landscape of relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukemia (B-ALL), with high remission rates across various CAR T-cell constructs. However, the durability of these responses remains a major challenge, with many patients experiencing relapse after an initial remission.
First-pass extracted concept
CAR T-cell therapy for relapsed/refractory B-cell precursor acute lymphoblastic leukemia
Candidate: concept label1 source documents3 linked claims
Live refresh every 5sNext refresh in 5s
Aliases
CAR T-cell therapy in R/R B-ALL
Evidence Snippets
Supporting Sources
Linked Claims
Although CAR T-cell therapy yields high remission rates in relapsed/refractory B-ALL, durability of response remains a major challenge because many patients relapse after initial remission.
Across 40 clinical trials in relapsed/refractory B-ALL, CAR T-cell therapy had a pooled complete remission rate of 83.4%.
Across 40 clinical trials in relapsed/refractory B-ALL, CAR T-cell therapy had a pooled MRD-negative complete remission or CRi rate of 92.7%.